JAMA pediatrics | 2021

Association of Maternal Autoimmune Disease With Attention-Deficit/Hyperactivity Disorder in Children.

 
 
 
 
 
 
 

Abstract


Importance\nMaternal autoimmune disease has been associated with increased risk of neurodevelopmental disorders in offspring, but few studies have assessed the association with attention-deficit/hyperactivity disorder (ADHD).\n\n\nObjective\nTo examine the association between maternal autoimmune disease and ADHD within a population-based cohort and combine results in a subsequent systematic review and meta-analysis.\n\n\nDesign, Setting, and Participants\nA cohort study was conducted of singleton children born at term gestation (37-41 weeks) in New South Wales, Australia, from July 1, 2000, to December 31, 2010, and followed up until the end of 2014; and a systematic review evaluated articles from the MEDLINE, Embase, and Web of Science databases to identify all studies published before November 20, 2019. A total of 12\u202f610 children exposed to maternal autoimmune disease were propensity score matched (1:4) to 50\u202f440 unexposed children, for a total cohort of 63\u202f050. A child was considered to have ADHD if they had (1) an authorization or filled prescription for stimulant treatment for ADHD or (2) a hospital diagnosis of ADHD. Children linked to a first ADHD event before 3 years of age were excluded. Data were analyzed from January 13 to April 20, 2020.\n\n\nExposures\nOne or more maternal autoimmune diagnoses in linked hospital admission records between July 1, 2000, and December 31, 2012. Thirty-five conditions were considered together and individually.\n\n\nMain Outcomes and Measures\nThe main outcome was child ADHD identified from stimulant authorization or prescription data and diagnoses in linked hospital admission records. Multivariable Cox regression was used to assess the association between maternal autoimmune disease and ADHD adjusted for child sex. Pooled hazard ratios (HRs) were calculated using random-effects meta-analysis with inverse-variance weights for each exposure reported by 2 or more studies.\n\n\nResults\nIn the population-based cohort analysis, 831\u202f718 singleton, term infants born to 831\u202f718 mothers (mean [SD] age, 29.8 [5.6] years) were assessed. Of 12\u202f767 infants (1.5%) who were linked to a maternal autoimmune diagnosis, 12\u202f610 were propensity score matched to 50\u202f440 control infants, for a total study cohort of 63\u202f050 infants. In this cohort, any autoimmune disease was associated with ADHD in offspring (HR, 1.30; 95% CI 1.15-1.46), as was type 1 diabetes (HR, 2.23; 95% CI, 1.66-3.00), psoriasis (HR, 1.66; 95% CI, 1.02-2.70), and rheumatic fever or rheumatic carditis (HR, 1.75; 95% CI, 1.06-2.89). Five studies (including the present study) were included in the meta-analysis. Any autoimmune disease (2 studies: HR, 1.20; 95% CI, 1.03-1.38), type 1 diabetes (4 studies: HR, 1.53; 95% CI, 1.27-1.85), hyperthyroidism (3 studies: HR, 1.15; 95% CI, 1.06-1.26), and psoriasis (2 studies: HR, 1.31; 95% CI, 1.10-1.56) were associated with ADHD.\n\n\nConclusions and Relevance\nIn this cohort study, maternal autoimmune diseases were associated with increased ADHD among children. These findings suggest possible shared genetic vulnerability between autoimmune disease and ADHD or a potential role for maternal immune activation in the expression of neurodevelopmental disorders in children. Future studies measuring disease activity, modifiers, and medication use are required to better understand the mechanisms underlying this association.

Volume None
Pages \n e205487\n
DOI 10.1001/jamapediatrics.2020.5487
Language English
Journal JAMA pediatrics

Full Text